OncoMatch/Clinical Trials/NCT05738694
Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma
Is NCT05738694 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Axitinib plus Toripalimab for renal cell carcinoma.
Treatment: Axitinib plus Toripalimab — The study included 298 RCC patients who were at high risk for recurrence after nephrectomy (T2G3-4 or T3-4 or N1). They were randomly divided to receive axitinib plus PD-1 + surgery or surgery alone at a ratio of 1:1, so as to determine the efficacy of the neoadjuvant combination of axitinib plus PD-1.
Check if I qualifyExtracted eligibility criteria
Cancer type
Renal Cell Carcinoma
Disease stage
Required: Stage T2G4, T2 WITH SARCOMATOID DIFFERENTIATION
Grade: G4
CT or MRI clinical staging is T2G4 or T2 with sarcomatoid differentiation, T3-4, N1
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
WBC≥3.5×10^9/L, absolute neutrophil count ≥1.5×10^9/L, PLT≥75.0×10^9/L, HGB≥80g/L
Kidney function
GFR ≥ 45 ml/min
Liver function
Total bilirubin ≤1.5×ULN, AST and ALT ≤2.5×ULN
Cardiac function
Cardiac function class 0-2
Sufficient heart, bone marrow, liver, and kidney functions: Cardiac function: Cardiac function class 0-2; Blood routine test: WBC≥3.5×10^9/L, absolute neutrophil count ≥1.5×10^9/L, PLT≥75.0×10^9/L, HGB≥80g/L; Liver function: Total bilirubin ≤1.5×ULN, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5×ULN; Renal function: GFR ≥ 45 ml/min.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify